[Circulating leptin doesn not change in postmenopausal women receiving replacement therapy with tibolone].
After informed consent, blood samples were obtained to measure leptin, FSH, LH, insulin, 17-beta-estradiol, and IGF-1. No differences in serum leptin was observed between the women on Tibolone (8.1 +/- 4.2 ng/mL) and the control group (7.4 +/- 3.7 ng/mL). Women on Tibolone had lower insulin levels (16.4 +/- 1.8) than women without therapy (19.4 +/- 1.3 mU/mL) (p < 0.05). On the contrary IGF-I levels were elevated (150.0 +/- 16.4) as compared with those in non-treated women (121.0 +/- 13.4 ng/mL) (p < 0.05). Body weight was similar between the two groups. From these data it is concluded that Tibolone, as replacement therapy, does not increase circulating leptin and seems to have no effect on body weight.
Basurto
L
L
Unidad de Investigación Médica en Enfermedades Endocrinas, Hospital de Especialidades del Centro Médico Nacional, IMSS, México, D.F.
Galván
R
R
Ochoa
R
R
Fonseca
E
E
Zárate
A
A
D000368:Aged; D001835:Body Weight / Q000187:drug effects; D004958:Estradiol / Q000097:blood; D015914:Estrogen Replacement Therapy; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D020738:Leptin / Q000097:blood*; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D009652:Norpregnenes / Q000737:chemistry / Q000494:pharmacology*; D017698:Postmenopause / Q000097:blood*; D011355:Prodrugs / Q000737:chemistry / Q000494:pharmacology; D020845:Selective Estrogen Receptor Modulators / Q000737:chemistry / Q000494:pharmacology*
D007328:Insulin; D020738:Leptin; D009652:Norpregnenes; D011355:Prodrugs; D020845:Selective Estrogen Receptor Modulators; D004958:Estradiol; D007334:Insulin-Like Growth Factor I; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; C027385:tibolone